✦ LIBER ✦

PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE

✍ Scribed by V Papagianopoulou; A Christodoulopoulou; A Bracco; I Yfantopoulos

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN104 A BUDGET IMPACT MODEL FOR THE INT

✍ V Papagiannopoulou; A Christodoulopoulou; A Bracco; I Yfantopoulos 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Cost-effectiveness of KRAS testing in me

✍ Arthi Vijayaraghavan; Molly B. Efrusy; Burkhard Göke; Thomas Kirchner; Christoph 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 394 KB

PCN70 Cost-Effectiveness of Cetuximab an

✍ Samyshkin, Y.; Hertel, N.; Griebsch, I. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

3617 POSTER Cost-Effectiveness of Cetuxi

✍ Samyshkin, Y.; Hertel, N.; Griebsch, I. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

6113 BRAF V600E mutation and Amphireguli

✍ Cremolini, C.; Loupakis, F.; Perrone, G.; Ruzzo, A.; Rulli, E.; Bencardino, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

No Survival Benefit from Adding Cetuxima

✍ Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yan 📂 Article 📅 2012 🏛 Public Library of Science 🌐 English ⚖ 533 KB